| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 寡肽化合物及其应用 | CN200980114258.1 | 2009-02-20 | CN102015758A | 2011-04-13 | 玛丽特·奥特雷; 佩尔·阿恩·阿斯; 艾玛道丁·菲兹 |
| 本发明提供了一种在治疗中使用的寡肽化合物或核酸分子，所述寡肽化合物包含PCNA相互作用基序，所述核酸分子包含编码所述寡肽化合物的序列，其中，所述PCNA相互作用基序是X1X2X3X3′X1′(SEQ ID NO：1)，其中X1和X1′独立选自碱性氨基酸组，X2是亲脂性氨基酸，而X3和X3′独立选自不带电荷的氨基酸组；并且其中所述寡肽化合物的进一步特征在于以下至少一个：(i)所述寡肽化合物包含至少一个信号序列；(ii)所述PCNA相互作用基序是[K/R]-F-[LIV]-[LIV]-[K/R](SEQ ID NO.27)。特别是，所述治疗可以是其中希望抑制细胞生长的病症或病况(例如快速增生性病症)的治疗，或者涉及细胞抑制治疗(例如骨髓细胞清除)的治疗。在某些方面，本发明的化合物就其性质可以用作细胞抑制剂。在本发明的其他方面，包含所述基序的寡肽化合物可以与细胞抑制剂联合使用，或者与放射性治疗联合使用。 | ||||||
| 2 | 寡肽化合物及其应用 | CN200980114258.1 | 2009-02-20 | CN102015758B | 2017-04-12 | 玛丽特·奥特雷; 佩尔·阿恩·阿斯; 艾玛道丁·菲兹 |
| 本发明提供了一种在治疗中使用的寡肽化合物或核酸分子，所述寡肽化合物包含PCNA相互作用基序，所述核酸分子包含编码所述寡肽化合物的序列，其中，所述PCNA相互作用基序是X1X2X3X3′X1′(SEQ ID NO：1)，其中X1和X1′独立选自碱性氨基酸组，X2是亲脂性氨基酸，而X3和X3′独立选自不带电荷的氨基酸组；并且其中所述寡肽化合物的进一步特征在于以下至少一个：(i)所述寡肽化合物包含至少一个信号序列；(ii)所述PCNA相互作用基序是[K/R]‑F‑[LIV]‑[LIV]‑[K/R](SEQ ID NO.27)。特别是，所述治疗可以是其中希望抑制细胞生长的病症或病况(例如快速增生性病症)的治疗，或者涉及细胞抑制治疗(例如骨髓细胞清除)的治疗。在某些方面，本发明的化合物就其性质可以用作细胞抑制剂。在本发明的其他方面，包含所述基序的寡肽化合物可以与细胞抑制剂联合使用，或者与放射性治疗联合使用。 | ||||||
| 3 | Stable Gene Transfer to Proliferating Cells | US15127743 | 2015-03-23 | US20170216456A1 | 2017-08-03 | Ian Alexander; Sharon Cunningham; Andras Nagy |
| Provided herein are methods for facilitating or inducing stable transgene integration and expression in a proliferating cell, comprising administering to the cell (i) a recombinant AAV (rAAV) vector comprising the transgene flanked by transposon-derived inverted terminal repeat sequences, which sequences are in turn flanked by AAV-derived inverted terminal repeat regions, and (ii) a source of a transposase that recognises said transposon-derived inverted terminal repeat sequences and directs the genomic integration of the transgene into the genome of the proliferating cell. Also provided are methods and transgene delivery systems for the treatment or prevention of diseases affecting, associated with or characterised by proliferating cells, including paediatric liver diseases, bone marrow diseases and cancer. | ||||||
| 4 | IMMUNE MODULATOR FOR IMMUNOTHERAPY AND VACCINE FORMULATION | US14652078 | 2013-12-14 | US20150315255A1 | 2015-11-05 | Xiang-Yang WANG; Xiaofei YU; John R. SUBJECK |
| A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF-KB-activating domain of Flagellin and an ATP-binding domain truncated Grp170. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease. | ||||||
| 5 | Oligopeptidic compounds and uses thereof | US12918797 | 2009-02-20 | US08871724B2 | 2014-10-28 | Marit Otterlei; Per Arne Aas; Emadoldin Feyzi |
| The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is X1X2X3X3′X1′- (SEQ ID NO: 1), wherein X1 and X1′- are independently selected from the group of basic amino acids, X2 is a lipophilic amino acid and X3 and X3′ are independently selected from the group of uncharged amino acids; and wherein the oligopeptidic compound is further characterized by at least one of the following: (i) the oligopeptidic compound comprises at least one signal sequence; (ii) the PCNA interacting motif is [K/R]-F-[L/I/V]-[L/I/V]-[K/R] (SEQ ID NO: 27). Particularly the therapy may be the treatment of a disorder or condition where it is desirable to inhibit the growth of cells, for example a hyperproliferative disorder, or a treatment which involves cytostatic therapy e.g., myeloablation. In certain aspects the compounds of the invention may be used as cytostatic agents in their own right. In other aspects of the invention oligopeptidic compounds comprising such a motif may be used in conjunction with cytostatic agents or with radiotherapy. | ||||||
| 6 | OLIGOPEPTIDIC COMPOUNDS AND USES THEREOF | US15586653 | 2017-05-04 | US20170246248A1 | 2017-08-31 | Marit Otterlei; Per Arne Aas; Emadoldin Feyzi |
| Disclosed is A method of treatment of a disorder or condition where it is desirable to inhibit the growth of cells, or a method of treatment which involves cytostatic therapy by administering an oligopeptidic compound to a subject in need thereof. The oligopeptidic compound is capable of interacting with proliferating cell nuclear antigen (PCNA) The compound comprises a PCNA interacting motif which is: which is: [K/R]-[F/Y/W]-[L/I/V/A/M]-[L/I/V/A/M]-[K/R] (SEQ ID NO. 28).The oligopeptidic compound has 9-70 subunits and at least one signal sequence. The signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence. In the compound a PCNA interacting motif is N-terminal to a signal sequence. | ||||||
| 7 | Oligopeptidic compounds and uses thereof | US14493728 | 2014-09-23 | US09676822B2 | 2017-06-13 | Marit Otterlei; Per Arne Aas; Emadoldin Feyzi |
| Disclosed is an oligopeptidic compound capable of interacting with proliferating cell nuclear antigen (PCNA), wherein the compound comprises a PCNA interacting motif which is: (SEQ ID NO. 28) [K/R]-[F/Y/W]-[L/I/V/A/M]-[L/I/V/A/M]-[K/R]; wherein the oligopeptidic compound has 9-70 subunits and comprises at least one signal sequence, wherein the signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence and wherein in said compound a PCNA interacting motif is N-terminal to a signal sequence. Also disclosed are methods of treatment of a disorder or condition where it is desirable to inhibit the growth of cells, or a method of treatment which involves cytostatic therapy, or a method of treatment of inflammation said method comprising administering the oligopeptidic compound to a subject in need thereof. | ||||||
| 8 | OLIGOPEPTIDIC COMPOUNDS AND USES THEREOF | US14493728 | 2014-09-23 | US20150017232A1 | 2015-01-15 | Marit OTTERLEI; Per Arne AAS; Emadoldin FEYZI |
| Disclosed is an oligopeptidic compound capable of interacting with proliferating cell nuclear antigen (PCNA), wherein the compound comprises a PCNA interacting motif which is: (SEQ ID NO. 28) [K/R]-[F/Y/W]-[L/I/V/A/M]-[L/I/V/A/M]-[K/R]; wherein the oligopeptidic compound has 9-70 subunits and comprises at least one signal sequence, wherein the signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence and wherein in said compound a PCNA interacting motif is N-terminal to a signal sequence. Also disclosed are methods of treatment of a disorder or condition where it is desirable to inhibit the growth of cells, or a method of treatment which involves cytostatic therapy, or a method of treatment of inflammation said method comprising administering the oligopeptidic compound to a subject in need thereof. | ||||||
| 9 | IMMUNE MODULATOR FOR IMMUNOTHERAPY AND VACCINE FORMULATION | US15795155 | 2017-10-26 | US20180105562A1 | 2018-04-19 | Xiang-Yang WANG; Xiaofei YU; John R. SUBJECK |
| A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF-κB-activating domain of Flagellin and an ATP-binding domain truncated Grp170. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease. | ||||||
| 10 | Immune modulator for immunotherapy and vaccine formulation | US14652078 | 2013-12-14 | US09822154B2 | 2017-11-21 | Xiang-Yang Wang; Xiaofei Yu; John R. Subjeck |
| A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF-KB-activating domain of Flagellin and an ATP-binding domain truncated Grp170. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease. | ||||||
| 11 | OLIGOPEPTIDIC COMPOUNDS AND USES THEREOF | US12918797 | 2009-02-20 | US20110020437A1 | 2011-01-27 | Marit Otterlei; Per Arne Aas; Emadoldin Feyzi |
| The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is X1X2X3X3′X1′″ (SEQ ED NO: 1), wherein X1 and X1′″ are independently selected from the group of basic amino acids, X2 is a lipophilic amino acid and X3 and X3′ are independently selected from the group of uncharged amino acids; and wherein the oligopeptidic compound is further characterised by at least one of the following: (i) the oligopeptidic compound comprises at least one signal sequence; (ii) the PCNA interacting motif is [K/R]-F-{LIV]-[LIV]-[K/R] (SEQ ID NO. 27). Particularly the therapy may be the treatment of a disorder or condition where it is desirable to inhibit the growth of cells, for example a hyperproliferative disorder, or a treatment which involves cytostatic therapy e.g. myeloablation. In certain aspects the compounds of the invention may be used as cytostatic agents in their own right. In other aspects of the invention oligopeptidic compounds comprising such a motif may be used in conjunction with cytostatic agents or with radiotherapy. | ||||||
| 12 | オリゴペプチド化合物及びその使用 | JP2015091311 | 2015-04-28 | JP6116614B2 | 2017-04-19 | オッターレイ マリット; アース ペル アーネ; フェイズィ エマドルディン |
| 13 | Oligo-peptide compounds and their use | JP2010547249 | 2009-02-20 | JP2011512150A | 2011-04-21 | ペル アーネ アース; マリット オッターレイ; エマドルディン フェイズィ |
| The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is X1X2X3X3′X1′″ (SEQ ED NO: 1), wherein X1 and X1′″ are independently selected from the group of basic amino acids, X2 is a lipophilic amino acid and X3 and X3′ are independently selected from the group of uncharged amino acids; and wherein the oligopeptidic compound is further characterised by at least one of the following: (i) the oligopeptidic compound comprises at least one signal sequence; (ii) the PCNA interacting motif is [K/R]-F-{LIV]-[LIV]-[K/R] (SEQ ID NO. 27). Particularly the therapy may be the treatment of a disorder or condition where it is desirable to inhibit the growth of cells, for example a hyperproliferative disorder, or a treatment which involves cytostatic therapy e.g. myeloablation. In certain aspects the compounds of the invention may be used as cytostatic agents in their own right. In other aspects of the invention oligopeptidic compounds comprising such a motif may be used in conjunction with cytostatic agents or with radiotherapy. | ||||||
| 14 | OLIGOPEPTIDIC COMPOUNDS AND USES THEREOF | EP09713402.7 | 2009-02-20 | EP2254904A2 | 2010-12-01 | OTTERLEI, Marit; AAS, Per, Arne; FEYZI, Ermadoldin |
| The oligopeptidic compound has 9-70 subunits and at least one signal sequence. The signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence. In the compound a PCNA interacting motif is N-terminal to a signal sequence. | ||||||
| 15 | OLIGOPEPTIDIC COMPOUNDS AND USES THEREOF | EP09713402.7 | 2009-02-20 | EP2254904B1 | 2018-04-11 | OTTERLEI, Marit; AAS, Per, Arne; FEYZI, Emadoldin |
| The oligopeptidic compound has 9-70 subunits and at least one signal sequence. The signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence. In the compound a PCNA interacting motif is N-terminal to a signal sequence. | ||||||
| 16 | STABLE GENE TRANSFER TO PROLIFERATING CELLS | EP15764909 | 2015-03-23 | EP3119896A4 | 2017-08-30 | ALEXANDER IAN; CUNNINGHAM SHARON; NAGY ANDRAS |
| Provided herein are methods for facilitating or inducing stable transgene integration and expression in a proliferating cell, comprising administering to the cell (i) a recombinant AAV (rAAV) vector comprising the transgene flanked by transposon-derived inverted terminal repeat sequences, which sequences are in turn flanked by AAV-derived inverted terminal repeat regions, and (ii) a source of a transposase that recognises said transposon-derived inverted terminal repeat sequences and directs the genomic integration of the transgene into the genome of the proliferating cell. Also provide are methods and transgene delivery systems for the treatment or prevention of diseases affecting, associated with or characterised by proliferating cells. | ||||||
| 17 | 올리고펩타이드 화합물 및 이의 용도 | KR1020177003734 | 2009-02-20 | KR1020170018485A | 2017-02-17 | 오터레이마릿; 아스페르아르네; 페이지에마돌딘 |
| 본발명은, 치료에사용하기위한, PCNA 상호작용모티프를포함하는올리고펩타이드화합물또는상기올리고펩타이드화합물을코딩하는서열을포함하는핵산분자를제공하며, 여기에서상기 PCNA 상호작용모티프는 XXXXX(서열번호 1)이고, X및 X은독립적으로염기성아미노산그룹으로부터선택되며, X는친지성아미노산이고, X및X은독립적으로비하전된아미노산그룹으로부터선택되며, 상기올리고펩타이드화합물은추가로 (i) 상기올리고펩타이드화합물은 1개이상의신호서열을포함함; (ii) 상기 PCNA 상호작용모티프는 [K/R]-F-[LIV]-[LIV]-[K/R] (서열번호 27)임중 한가지이상으로특정된다. 특히, 상기치료는, 세포의생장을저해하는것이바람직한질환이나상태, 예컨대과증식성질환의치료, 또는세포증식억제요법, 예컨대골수말소를수반하는치료일수 있다. 특정측면에서, 본발명의화합물은그 자체를세포증식억제제로사용할수 있다. 본발명의다른측면에서, 상기한모티프를포함하는올리고펩타이드화합물은세포증식억제제나방사선치료와함께사용할수 있다. | ||||||
| 18 | 올리고펩타이드 화합물 및 이의 용도 | KR1020107020864 | 2009-02-20 | KR101653774B1 | 2016-09-05 | 오터레이마릿; 아스페르아르네; 페이지에마돌딘 |
| 본발명은, 치료에사용하기위한, PCNA 상호작용모티프를포함하는올리고펩타이드화합물또는상기올리고펩타이드화합물을코딩하는서열을포함하는핵산분자를제공하며, 여기에서상기 PCNA 상호작용모티프는 XXXXX(서열번호 1)이고, X및 X은독립적으로염기성아미노산그룹으로부터선택되며, X는친지성아미노산이고, X및X은독립적으로비하전된아미노산그룹으로부터선택되며, 상기올리고펩타이드화합물은추가로 (i) 상기올리고펩타이드화합물은 1개이상의신호서열을포함함; (ii) 상기 PCNA 상호작용모티프는 [K/R]-F-[LIV]-[LIV]-[K/R] (서열번호 27)임중 한가지이상으로특정된다. 특히, 상기치료는, 세포의생장을저해하는것이바람직한질환이나상태, 예컨대과증식성질환의치료, 또는세포증식억제요법, 예컨대골수말소를수반하는치료일수 있다. 특정측면에서, 본발명의화합물은그 자체를세포증식억제제로사용할수 있다. 본발명의다른측면에서, 상기한모티프를포함하는올리고펩타이드화합물은세포증식억제제나방사선치료와함께사용할수 있다. | ||||||
| 19 | 올리고펩타이드 화합물 및 이의 용도 | KR1020177003734 | 2009-02-20 | KR101758671B1 | 2017-07-17 | 오터레이마릿; 아스페르아르네; 페이지에마돌딘 |
| 본발명은, 치료에사용하기위한, PCNA 상호작용모티프를포함하는올리고펩타이드화합물또는상기올리고펩타이드화합물을코딩하는서열을포함하는핵산분자를제공하며, 여기에서상기 PCNA 상호작용모티프는 XXXXX(서열번호 1)이고, X및 X은독립적으로염기성아미노산그룹으로부터선택되며, X는친지성아미노산이고, X및X은독립적으로비하전된아미노산그룹으로부터선택되며, 상기올리고펩타이드화합물은추가로 (i) 상기올리고펩타이드화합물은 1개이상의신호서열을포함함; (ii) 상기 PCNA 상호작용모티프는 [K/R]-F-[LIV]-[LIV]-[K/R] (서열번호 27)임중 한가지이상으로특정된다. 특히, 상기치료는, 세포의생장을저해하는것이바람직한질환이나상태, 예컨대과증식성질환의치료, 또는세포증식억제요법, 예컨대골수말소를수반하는치료일수 있다. 특정측면에서, 본발명의화합물은그 자체를세포증식억제제로사용할수 있다. 본발명의다른측면에서, 상기한모티프를포함하는올리고펩타이드화합물은세포증식억제제나방사선치료와함께사용할수 있다. | ||||||
| 20 | 올리고펩타이드 화합물 및 이의 용도 | KR1020107020864 | 2009-02-20 | KR1020100123728A | 2010-11-24 | 오터레이마릿; 아스페르아르네; 페이지에마돌딘 |
| 본 발명은, 치료에 사용하기 위한, PCNA 상호작용 모티프를 포함하는 올리고펩타이드 화합물 또는 상기 올리고펩타이드 화합물을 코딩하는 서열을 포함하는 핵산 분자를 제공하며, 여기에서 상기 PCNA 상호작용 모티프는 X
1 X
2 X
3 X
3' X
1' (서열번호 1)이고, X
1
및 X
1' 은 독립적으로 염기성 아미노산 그룹으로부터 선택되며, X
2 는 친지성 아미노산이고, X
3
및
X
3' 은 독립적으로 비하전된 아미노산 그룹으로부터 선택되며, 상기 올리고펩타이드 화합물은 추가로 (i) 상기 올리고펩타이드 화합물은 1개 이상의 신호 서열을 포함함; (ii) 상기 PCNA 상호작용 모티프는 [K/R]-F-[LIV]-[LIV]-[K/R] (서열번호 27)임 중 한가지 이상으로 특정된다. 특히, 상기 치료는, 세포의 생장을 저해하는 것이 바람직한 질환이나 상태, 예컨대 과증식성 질환의 치료, 또는 세포증식 억제 요법, 예컨대 골수 말소를 수반하는 치료일 수 있다. 특정 측면에서, 본 발명의 화합물은 그 자체를 세포증식 억제제로 사용할 수 있다. 본 발명의 다른 측면에서, 상기한 모티프를 포함하는 올리고펩타이드 화합물은 세포증식 억제제나 방사선치료와 함께 사용할 수 있다.
|
||||||
QQ群二维码
意见反馈
意见反馈